Skip to main content
SpringerLink
Log in

An Overview of the Regulatory and Developmental Strategies of Chronotherapeutics

  • Clinical Trials: Review
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

The pivotal idea toward the development of chronotherapeutics is synchronizing the in vivo drug bioavailability with the rhythms of the disease to optimize therapeutic outcomes and minimize side effects, which is contrary to the homeostatic theory of drug delivery. The advent of formulation technologies, marketing exclusivities of innovative products, and provisions/amendments in regulatory frameworks have led to the development of commercial chronotherapeutic products, but their numbers are few and are confined mainly to diseases of the cardiovascular system. A major bottleneck for its development would be the understanding of rhythmic variations of disease, but following regulatory pathways for commercial development has always been challenging. In this article, a few commercial products have been investigated in view of their developmental strategies in order to find out the minimum preclinical and clinical studies needed for the development of chronotherapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haus E. Chronobiology in the endocrine system. Adv Drug Deliv Rev. 2007;59:985–1014.

    Article  CAS  Google Scholar 

  2. Lamberg L. Chronotherapeutics: implications for drug therapy. Am Pharm. 1991;11:20–23.

    Article  Google Scholar 

  3. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2:307–315.

    Article  CAS  Google Scholar 

  4. Gherghel D, Hosking SL, Orgül S. Autonomic nervous system, circadian rhythms, and primary open-angle glaucoma. Surv Ophthalmol. 2004;49:491–508.

    Article  Google Scholar 

  5. Ohdo S. Chronopharmacology focused on biological clock. Drug Metab Pharmacokin. 2007;22:3–14.

    Article  CAS  Google Scholar 

  6. Ravisankar V, Reddy YD, Rao AN, Dhachinamoorthy D, Chandrasekhar K. Chronotherapeutics: an art of dosage form designing. J Pharm Res. 2010;3:1690–1696.

    Google Scholar 

  7. FDA. Draft Guidance for Industry: Applications Covered by Section 505(b)(2). October 1999. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm079345.pdf. Accessed February 2016.

  8. Ministry of Health and Family Welfare, Government of India. Guidelines for Bioavailability and Bioequivalence Studies. 2005.

  9. European Medicines Agency. European Medicines Agency Guidance for Data Exclusivity/Generics/Biosimilars: Regulatory and Procedural Guidance. April 4, 2012.

  10. Douglas JG. Saturday, May 18, 6:30 AM–8.00 AM: compliance with antihypertensive therapy: is it time for chronotherapy?*: is it time for chronotherapy? Am J Hypertens. 2002;15:238A.

    Article  Google Scholar 

  11. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59:828–851.

    Article  CAS  Google Scholar 

  12. Mehl AB. The Hatch-Waxman Act and market exclusivity for generic manufacturers: an entitlement or an incentive? Chicago-Kent Law Review. 2006; 81(2):649.

    Google Scholar 

  13. Sangalli M, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Control Release. 2001;73:103–110.

    Article  CAS  Google Scholar 

  14. Sher P, Ingavle G, Ponrathnam S, Pawar AP. Low density porous carrier based conceptual drug delivery system. Micropor Mesopor Mater. 2007;102:290–298.

    Article  CAS  Google Scholar 

  15. Khan Z, Pillay V, Choonara YE, du Toit LC. Drug delivery technologies for chronotherapeutic applications. Pharm Dev Technol. 2009;14:602–612.

    Article  CAS  Google Scholar 

  16. Björn L. Implications of chronopharmacokinetics for drug delivery: antiasthmatics, H 2-blockers and cardiovascular active drugs. Adv Drug Deliv Rev. 1991;6:83–100.

    Article  Google Scholar 

  17. Goo R, Moore J, Greenberg E, Alzraki N, eds. Circadian variation in gastric-emptying of meals in man. Gastroenterology. Philadelphia, PA: WB Saunders; 1987.

  18. Youan BBC. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J Control Release. 2004;98:337–353.

    Article  CAS  Google Scholar 

  19. Tinny T, Chacko AJ, Jose S. Formulation development and statistical optimization of chronotherapeutic tablets of indomethacin. Drug Dev Ind Pharm. 2013;39:1357–1363.

    Article  CAS  Google Scholar 

  20. Khadabadi SS, Chishti NH, Khan FM, Tadvee AA. Formulation and evaluation of press coated tablet of ketoprofen—a chronotherapeutic approach. Int J Pharm Pharm Sci. 2013;5:733–740.

    CAS  Google Scholar 

  21. Hadi MA, Rao NGR, Rao AS. Formulation and evaluation of mini-tablets-filled-Pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis. Pak J Pharm Sci. 2015;28:185–193.

    PubMed  Google Scholar 

  22. Hadi MA, Rao NGR, Rao AS. Formulation and evaluation of ileo-colonic targeted matrix-mini-tablets of naproxen for chronotherapeutic treatment of rheumatoid arthritis. Saudi Pharm J. 2016;24:64–73.

    Article  Google Scholar 

  23. Qureshi J, Ali J, Baboota S, Ahuja A, Mallikarjun C. Development and evaluation of chronotherapeutic drug delivery system for the management of nocturnal asthma. Trop J Pharm Res. 2012;11:703–712.

    CAS  Google Scholar 

  24. Ansari KA, Pagar KP, Anwar S, Vavia PR. Design and optimization of self-microemulsifying drug delivery system (SMEDDS) of felodipine for chronotherapeutic application. Braz J Pharm Sci. 2014;50:203–212.

    Article  CAS  Google Scholar 

  25. Stevens HNE, Wilson CG, Welling PG, et al. Evaluation of Pulsincap™ to provide regional delivery of dofetilide to the human GI tract. Int J Pharm. 2002;236:27–34.

    Article  CAS  Google Scholar 

  26. Al-Zoubi N, Alkhatib HS, Alobaidi G, Abdel-Rahim S, Obeidat W, Malamataris S. Optimization of pH-independent chronotherapeutic release of verapamil HCl from three-layer matrix tablets. Int J Pharm. 2015;494:296–303.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Regulatory Affairs, Sun Pharmaceutical Industries Ltd, Haryana, India

    Mohd. Aamir Mirza PhD

  2. Center of Excellence in Biotechnology Research (CEBR), King Saud University, PO Box 2460, Riyadh, 11451, Saudi Arabia

    Faiyaz Shakeel PhD

  3. Deptartment of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India

    Zeenat Iqbal PhD

Authors
  1. Mohd. Aamir Mirza PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faiyaz Shakeel PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zeenat Iqbal PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Faiyaz Shakeel PhD or Zeenat Iqbal PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mirza, M.A., Shakeel, F. & Iqbal, Z. An Overview of the Regulatory and Developmental Strategies of Chronotherapeutics. Ther Innov Regul Sci 50, 450–454 (2016). https://doi.org/10.1177/2168479016634147

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479016634147

Keywords

Search

Navigation